The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Axicabtagene ciloleucel in the real-world: safety and efficacy
David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, discusses two major abstracts assessing axicabtagene ciloleucel for refractory aggressive non-Hodgkin lymphoma, given in a real-world setting where treatment eligibility may differ from clinical trials, with the ZUMA-1 study (NCT02348216) a key topic of talk. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dr Maloney reveals the efficacy and safety results, with the retrospective analysis of the real-world cohort showing important distinctions from ZUMA-1.
